A Food and Drug Administration advisory panel will review Aveo Pharmaceuticals Inc.'s (Nasdaq: AVEO) kidney cancer treatment tivozanib to determine if further study is needed. The stock price plummeted $2.33 to close at $5.11.
FDA Advisory Panel To Review Aveo's Drug
April 30, 2013 at 17:30 PM EDT
